Orlando Regional Medical Center is an 808-bed tertiary hospital in downtown Orlando, Florida designed by HKS, Inc. and Walter P Moore. It is the flagship of the Orlando Health system.

There are 808 beds in Orlando Health.

During the past decade, Orlando Health conducted 103 clinical trials. In the 10-year time frame, 103 clinical trials started and 51 clinical trials were completed, i.e. on average, 49.5% percent of trials that started reached the finish line to date. In the past 5 years, 47 clinical trials started and 33 clinical trials were completed. i.e. 70.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Orlando Health" #1 sponsor was "Bristol-Myers Squibb" with 10 trials, followed by "Orlando Health, Inc." with 9 trials sponsored, "Pfizer" with 9 trials sponsored, "Abbott Medical Devices" with 7 trials sponsored and "Hoffmann-La Roche" with 7 trials sponsored. Other sponsors include 94 different institutions and companies that sponsored additional 84 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Orlando Health" #1 collaborator was "Bristol-Myers Squibb" with 4 trials as a collaborator, "Medivation, Inc." with 4 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 4 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 4 trials as a collaborator and "AstraZeneca" with 3 trials as a collaborator. Other collaborators include 74 different institutions and companies that were collaborators in the rest 75 trials.

According to Clinical.Site data, the most researched conditions in "Orlando Health" are "Breast Cancer" (7 trials), "Melanoma" (6 trials), "Coronary Artery Disease" (5 trials), "Breast Neoplasms" (4 trials) and "Heart Failure" (4 trials). Many other conditions were trialed in "Orlando Health" in a lesser frequency.

Most popular intervention types in "Orlando Health" are "Drug" (79 trials), "Device" (27 trials), "Biological" (14 trials), "Procedure" (14 trials) and "Other" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Nivolumab" (8 trials), "Ipilimumab" (6 trials), "Atezolizumab" (5 trials) and "Bevacizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Orlando Health" are 128 trials for "All" genders, 10 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Orlando Health". undefined are not yet recruiting, 41 are recruiting, 24 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 59 completed trials in Orlando Health, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Orlando Health, 12 "Phase 1" clinical trials were conducted, 33 "Phase 2" clinical trials and 49 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 36 trials that are defined as “Not Applicable".

Orlando Health has several departments that took part in Clinical trials: "Orlando Health Cancer Institute" - 247 trials, "MD Anderson Cancer Center Orlando" - 154 trials, "Cancer Centers of Florida, P.A." - 42 trials, "Orlando Heart Center" - 21 trials, "Jewett Orthopaedic Clinic" - 5 trials, "Florida ID Group" - 3 trials, "UF Health Center at Orlando Health" - 2 trials, "MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children" - 2 trials, "Gynecologic Cancer Center" - 2 trials